目的 研究拉貝洛爾聯(lián)合尼莫地平對(duì)妊娠高血壓患者血液流變學(xué)和氧化應(yīng)激的影響。方法 選擇2013年1月—2017年12月長(zhǎng)安醫(yī)院收治的80例妊娠高血壓患者作為研究對(duì)象，將患者隨機(jī)分為對(duì)照組和觀察組，每組各40例。對(duì)照組患者口服尼莫地平片，20 mg/次，1次/d。觀察組在對(duì)照組的基礎(chǔ)上口服鹽酸拉貝洛爾片，1片/次，3次/d。兩組均持續(xù)治療10 d。觀察兩組患者的臨床療效和妊娠結(jié)局，同時(shí)比較兩組治療前后的血液流變學(xué)和氧化應(yīng)激情況。結(jié)果 治療后，觀察組的總有效率為90.00%，顯著高于對(duì)照組的77.50%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，觀察組的各不良妊娠發(fā)生率均顯著低于對(duì)照組（P<0.05），自然分娩率顯著高于對(duì)照組（P<0.05）。兩組治療后的丙二醛（MDA）和超氧化物歧化酶（SOD）水平均改善（P<0.05），且觀察組MDA和SOD水平顯著優(yōu)于對(duì)照組（P<0.05）。治療后，兩組血小板聚集率和血液黏稠度均顯著降低（P<0.05）；治療后，觀察組血小板聚集率和血液黏稠度顯著低于對(duì)照組（P<0.05）。結(jié)論 拉貝洛爾聯(lián)合尼莫地平可以改善妊娠高血壓患者的妊娠情況，提高治療有效率，改善血液流變學(xué)和氧化應(yīng)激水平。

Objective To study the effect of labetalol combined with nimodipine on hemorheology and oxidative stress in pregnant hypertensive patients. Methods A total of 80 patients with gestational hypertension admitted to Chang'an Hospital from January 2013 to December 2017 were selected as the study subjects, and randomly divided into control group and an observation group, with 40 patients in each group. Patiens in the control group were po administered with Nimodipine Tablets, 20 mg/time and once daily. Patiens in the observation group were po administered with Labetalol Hydrochloride Tablets on the basis of control group, 1 tablet/time, three times daily. Both groups were treated continuously for 10 d. The clinical efficacy and pregnancy status in two groups were observed, and the hemorheology and oxidative stress in two groups before and after treatment were compared. Results After treatment, the total effective rate of the observation group was 90.00%, which was significantly higher than 77.50% of the control group, and the difference between two groups was statistically significant (P<0.05). After treatment, the incidence of adverse pregnancy in the observation group was significantly lower than that in the control group (P<0.05), and the rate of natural delivery was significantly higher than that in the control group (P<0.05). After treatment, MDA and SOD levels in two groups were improved (P<0.05), and MDA and SOD levels in the observation group were significantly better than those in the control group (P<0.05). After treatment, the platelet aggregation rate and blood viscosity were decreased significantly in two groups (P<0.05). After treatment, the platelet aggregation rate and blood viscosity in the observation group were significantly lower than those in the control group (P<0.05). Conclusion Labetalol combined with nimodipine can improve the pregnancy status of pregnant hypertensive patients, improve the effective rate of treatment, and improve the level of hemorheology and oxidative stress.

R984;R972